2024-05-16 – Topline results of the Phase 1b/2a clinical trial anticipated mid-year 2024 – Miami – May 16, 2024 – Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the completion of the last patient’s

2024-04-16 MIAMI, March 25, 2024 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will host a virtual key opinion leader (“KOL”) event highlighting expert perspectives on spinal bulbar muscular

2024-01-02 – Topline data remains on track for second quarter of 2024 – Miami, FL – January 2, 2024 – Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that all patients have been enrolled

2023-12-11 President Tsai Ing-wen hosted the recipients of the “2023 Outstanding Company” Award at the Presidential Palace on December 8, 2023. Dr. Nick Li attended the reception on behalf of AnnJi Pharmaceutical Co. (AnnJi), the winner of the “Emerging Company of the Year “. AnnJi is an R&D based, clinical-stage new drug company dedicated to

Topline data expected in 2024 MIAMI, July 27, 2023 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that the first patient has been dosed in the Phase 1b/2a clinical trial of

TAIPEI, March 14, 2023 /PRNewswire/ — AnnJi Pharmaceutical Co. (AnnJi) has entered into an exclusive license agreement with Avenue Therapeutics Inc. (Avenue, NASDAQ: ATXI) for the development and commercialization of AJ201 in the U.S., Canada, European Union, Great Britain, and Israel for spinal and bulbar muscular atrophy (SBMA), also known as Kennedy’s Disease. Under the